Kardigan, Inc. is a clinical-stage precision therapeutics company. It is developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Its pipeline of products includes Danicamtiv, Ataciguat and Tonlamarsen. Danicamtiv is an investigational oral cardiac atrial and ventricular myosin activator for the treatment of genetic dilated cardiomyopathy caused by pathogenic variants in myosin heavy chain 7 (MYH7) and titin, the common sarcomeric gene variants. Ataciguat is an investigational oral, once-daily soluble guanylate cyclase activator aimed at slowing the progression of calcific aortic valve stenosis in patients with moderate diseases. Tonlamarsen is an investigational liver-directed antisense oligonucleotide administered once-monthly via subcutaneous injection, targeting hepatic angiotensinogen for the management of blood pressure in acute severe hypertension post-hospitalization. Prolaio is a clinical intelligence platform.
Ticker SymbolKARD
Company nameKardigan Inc
IPO dateJun 18, 2026
CEOGianakakos (Tassos Anastasios)
Number of employees420
Security typeOrdinary Share
Fiscal year-endJun 18
Address506 Carnegie Center Drive, Suite 201
CityPRINCETON JUNCTION
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08540
Phone14155733220
Websitehttp://www.kardigan.bio
Ticker SymbolKARD
IPO dateJun 18, 2026
CEOGianakakos (Tassos Anastasios)